Orchestra BioMed Inc. announced it has formed a global strategic partnership with Terumo Corp. for development and commercialization of the Virtue Sirolimus-Eluting Balloon (SEB), one of Orchestra...
TCT
This channel contains news about the annual Transcatheter Cardiovascular Therapeutics (TCT) conference presented by the Cardiovascular Research Foundation (CRF). It includes coverage from the annual meeting and links CRF news. TCT is the premier conference for the subspecialty of interventional cardiology, including the new subspecialty areas of transcatheter structural heart procedures.
-
-
W. L. Gore & Associates (Gore) announced the U.S. Food and Drug Administration’s (FDA’s) premarket approval (PMA) of the Gore Cardioform ASD Occluder for the percutaneous closure of ostium...
-
Cordis, a Cardinal Health company, recently announced the full U.S. launch of its Radial 360 portfolio, offering a complete range of products to facilitate the transradial approach (TRA) for...
-
Boston Scientific Corp. announced it has received U.S. Food and Drug Administration (FDA) approval for the Lotus Edge Aortic Valve System. Delivered via a minimally invasive procedure, this...
News | Drug-Eluting Balloons | June 13, 2019
June 13, 2019 — Orchestra BioMed Inc. announced it has formed a global strategic partnership with Terumo Corp. for...
Technology | Structural Heart Occluders | June 10, 2019
June 10, 2019 – W. L. Gore & Associates (Gore) announced the U.S. Food and Drug Administration’s (FDA’s)...
Technology | Radial Access | May 15, 2019
May 15, 2019 — Cordis, a Cardinal Health company, recently announced the full U.S. launch of its Radial 360...
Feature | Heart Valve Technology | April 23, 2019 | Dave Fornell, Editor
April 23, 2019 — The U.S. Food and Drug Administration (FDA) has cleared the Boston Scientific Lotus Edge...
Feature | Heart Valve Technology | March 14, 2019 | Jeff Zagoudis, Associate Editor
March 14, 2019 — The U.S. Food and Drug Administration (FDA) approved the MitraClip...
A comparison of stent strut thickness between the Orsiro stent, pictured, and the market-leading stents on the U.S. and European markets. Vendors have been working toward reducing strut thickness to help improve overall clinical outcomes. Orsiro is now the smallest strut stent available on the market.
Feature | Stents | February 22, 2019 | Dave Fornell, Editor
February 22, 2019 — The U.S. Food and Drug Administration (FDA) has approved the Biotronik Orsiro drug-eluting stent...
The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.
Feature | Peripheral Artery Disease (PAD) | January 30, 2019 | Dave Fornell, Editor
In recent years, there has been a lot of focus by vendors on developing better stenting technologies to treat...
Technology | Heart Valve Technology | January 02, 2019
January 2, 2019 — Edwards Lifesciences Corp. announced that the Sapien 3 Ultra system has received U.S. Food and...
News | Angiography | October 17, 2018
October 17, 2018 — Shimadzu Medical Systems USA and Change Healthcare have entered a partnership through which...
The cardiovascular innovation cycle, presented by TCT Course Director Martin Leon, M.D., at TCT 2018.
Blog | Cath Lab | October 16, 2018
There is a hype cycle surrounding new technologies in all industries, but medicine is unique because of its focus on...
An example of the new transesophageal echo (TEE) visualization technology called TrueVue was shown at TCT 2018 for the first time. Philips’ new photo-realistic rendering is designed to offer a surgical view of cardiac structures to aid transcatheter procedural navigation. The technology also allows the lighting source to be moved around and even behind the anatomy, as demonstrated here. This video, included as part of the most innovative technologies video at TCT 2018, went viral when posted on social media during TCT 2018, and was viewed more than 167,000 times.
Blog | TCT | October 15, 2018
From a cardiovascular device innovation standpoint, the 2018...
Bioresorbable stents (BRS) in development, presented by Gregg Stone, M.D., during TCT 2017. Several of the players listed on the slider put their BRS development programs on hold after the negative data from the ABSORB III Trial, but a handful of smaller companies are still pushing the technology forward.
Feature | Stents Bioresorbable | October 12, 2018 | Dave Fornell, Editor
Bioresorbable stent (BRS) technology is not dead, but the unbridled enthusiasm seen two years ago for the technology...
A comparison of target lesion failure (TLF) of the Reva bioresorbable stent to the Absorb and top performing metallic DES.
News | Stents Bioresorbable | October 12, 2018
October 12, 2018 – Reva Medical presented four key data sets demonstrating the capabilities of the company’s Fantom...
